| Patient | Zora Neale Hurston |
|---|---|
| Date of birth | 1891-01-07 |
| Identifiers | MRN HR-ML040-SYN-TD; SSN (made up) 000-40-6213 |
| Document date | 1958-10-19 |
| Author | Lorraine Abernathy-Osei, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Seven-month review: blood pressure, heart failure and screening results. [S]
Ms. Hurston returns five weeks after her annual wellness visit. She is substitute teaching two or three days a week and finishing a chapter of her new book. She walks to the bus without stopping and has had no lightheadedness, chest pain or swelling. Her home blood pressure average is 122/74. Her drug plan with Extra Help now supplies all five medicines in 90-day fills. Her screening results: the stool test (FIT) was negative, the mammogram was normal, the hepatitis C antibody was negative, and the bone density scan showed osteopenia (lowest T-score -1.6 at the femoral neck) with a ten-year risk of hip fracture below the level at which medicine is advised. The optometrist found mild hypertensive changes in the retinas without bleeding or swelling. She would like her zoster and Tdap vaccines today. [S]
| Element | Detail |
|---|---|
| Home blood pressure | Average 122/74 mmHg |
| Function | NYHA class I to II; teaching two or three days a week |
| Screening | FIT, mammogram and hepatitis C negative; osteopenia, below the treatment threshold |
| Eyes | Mild hypertensive retinopathy; no hemorrhage or swelling |
| KCCQ-12 | 78 |
| System | Result | Finding |
|---|---|---|
| Cardiovascular | Negative | No chest pain, palpitations or edema |
| Neurological | Negative | No headache, lightheadedness, weakness, numbness, speech or vision change |
| Musculoskeletal | Negative | No falls |
3 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Amlodipine 5 mg oral tablet, one tablet every morning | One tablet every morning | Oral route | 1958-03-09 | active | S |
| Chlorthalidone 25 mg oral tablet, one-half tablet (12.5 mg) every morning | One-half tablet every morning | Oral route | 1958-03-09 | active | S |
| Dapagliflozin 10 mg oral tablet, one tablet daily; pause on days of vomiting, diarrhea or not eating or drinking | One tablet daily, with sick-day rules | Oral route | 1958-03-23 | active | S |
| Atorvastatin 20 mg oral tablet, one tablet daily | One tablet daily | Oral route | 1958-03-23 | active | S |
| Spironolactone 25 mg oral tablet, one-half tablet (12.5 mg) daily | One-half tablet daily | Oral route | 1958-04-06 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1958-10-19 | Body height | 165 | cm | S |
| 1958-10-19 | Body weight | 81.2 | kg | S |
| 1958-10-19 | Body mass index (BMI) [Ratio] | 29.8 | kg/m2 | S |
| 1958-10-19 | Systolic blood pressure | 124 | mm[Hg] | S |
| 1958-10-19 | Diastolic blood pressure | 74 | mm[Hg] | S |
| 1958-10-19 | Heart rate | 70 | /min | S |
| 1958-10-19 | Respiratory rate | 16 | /min | S |
| 1958-10-19 | Body temperature | 36.5 | Cel | S |
| 1958-10-19 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1958-10-19 | Sodium [Moles/volume] in Serum or Plasma | 139 | mmol/L | 135-145 mmol/L | Normal | S |
| 1958-10-19 | Potassium [Moles/volume] in Serum or Plasma | 4.3 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 1958-10-19 | Creatinine [Mass/volume] in Serum or Plasma | 0.92 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 1958-10-19 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1953)/1.73 sq M | 68 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 1958-10-19 | Glucose [Mass/volume] in Serum or Plasma | 96 | mg/dL | 70-99 mg/dL | Normal | S |
| 1958-10-19 | Magnesium [Mass/volume] in Serum or Plasma | 2 | mg/dL | 1.6-2.6 mg/dL | Normal | S |
| 1958-10-19 | Overall summary score [KCCQ-12] | 78 | {score} | S |
Vital signs recorded on 1958-10-19; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; blood pressure 124/74, pulse 70; weight 81.2 kg |
| Neck | Jugular venous pressure not raised |
| Cardiovascular | Regular rhythm; soft S4 |
| Respiratory | Clear |
| Extremities | No edema |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Very high blood pressure at intake (178/104 and 174/102 mmHg) with morning headaches for two months, without signs of a hypertensive emergency; not previously diagnosed; ambulatory monitoring to confirm | resolved | confirmed | R03.0 | S — Synthetic presenting problem, resolved when ambulatory monitoring and the echocardiogram established the diagnosis at the second visit. Not a claim about her real blood pressure. |
| Breathlessness on exertion for three months (walking to the school, carrying groceries) with mild ankle swelling by evening; cause to be determined | resolved | confirmed | R06.09 | S — Synthetic presenting problem, resolved into the heart failure diagnosis at the second visit. |
| Hypertensive heart disease with heart failure: stage 2 hypertension confirmed by 24-hour ambulatory monitoring (mean 158/96 mmHg, non-dipping at night), with concentric left ventricular hypertrophy on ECG and echocardiogram; synthetic modern episode linked to the hypertensive heart disease recorded as her cause of death | active | confirmed | I11.0 | S — Synthetic modern diagnosis made at the second visit; the 1960 cause of death remains D. |
| Heart failure with preserved ejection fraction (ejection fraction 62%), NYHA class II, with grade II diastolic dysfunction and an enlarged left atrium | active | confirmed | I50.32 | S — Synthetic modern diagnosis confirmed by echocardiogram and cardiology at the second visit. |
| Food insecurity: food runs short at the end of most months (Hunger Vital Sign positive) | active | confirmed | Z59.41 | S — Synthetic social need anchored to her documented poverty. |
| Low and irregular income from substitute teaching and newspaper writing, with Original Medicare but no drug coverage; medicine costs a barrier | active | confirmed | Z59.6 | S — Synthetic social need anchored to her documented low income in the 1950s. |
| Orthostatic hypotension with lightheadedness on standing, from volume depletion in early summer heat on a diuretic, spironolactone and an SGLT2 inhibitor; no fall or faint; resolved after two days off those medicines and more fluid | resolved | confirmed | I95.1 | S — Synthetic intercurrent problem at an unscheduled visit; it follows from the treatment plan and the climate and does not echo a documented illness. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Blood pressure in the clinic (seated, average of two readings, large cuff) | Every visit | Completed today | 124/74 mmHg |
| Examination | Out-of-office blood pressure (ambulatory at diagnosis; home readings when treatment changes) | At diagnosis and with each treatment change | Completed today | Home average 122/74 mmHg |
| Examination | Weight, volume status (jugular venous pressure, edema, lungs) and NYHA class | Every visit | Completed today | 81.2 kg; jugular venous pressure not raised; no edema; NYHA I to II |
| Laboratory | Metabolic panel (sodium, potassium, creatinine and eGFR) and magnesium | Every three to six months when stable | Completed today | Sodium 139, potassium 4.3, creatinine 0.92 mg/dL (eGFR 68), magnesium 2.0 |
| Survey | KCCQ-12 heart failure health status | At diagnosis, then every three to six months | Completed today | 78 |
| Laboratory | Lipid panel | Four to twelve weeks after starting a statin; then yearly | Up to date | LDL 76 mg/dL at the eight-week review; next at one year |
| Laboratory | Urine albumin-to-creatinine ratio | Yearly | Up to date | 22 mg/g at intake; due at one year |
| Laboratory | Hemoglobin A1c | Yearly | Up to date | 5.6% at intake; due at one year |
| Imaging | ECG and echocardiogram | At diagnosis; repeat only with unexplained clinical change | Not indicated | Stable; no unexplained change |
| Survey | Depression screen (PHQ-2, then PHQ-9 if positive) | Yearly | Up to date | PHQ-2 0 at the wellness visit |
| Examination | Eye examination for hypertensive retinopathy | Yearly | Up to date | Dilated optometry examination since the wellness visit: mild hypertensive retinopathy without hemorrhage or swelling |
| Self-management | Self-care: daily weights, less salt, sick-day rules and the BE FAST stroke signs | Every visit | Completed today | Weighs daily; heat plan through the summer; BE FAST reviewed |
| Medication safety | Medicine costs and coverage (generics, 90-day fills, patient assistance, Extra Help, Medicare Savings Program) | Every visit | Completed today | All five medicines through her drug plan with Extra Help, in 90-day fills |
| Self-management | Food access | Every visit | Completed today | Food lasts the month |
Goal progress:
Immunizations given today: Recombinant zoster vaccine, dose 1 of 2; Tetanus, diphtheria, and acellular pertussis vaccine (Tdap) [S]
Guideline basis: 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults (2025); 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure (2022); CMID: Clinical Monitoring Intelligence Database, hypertension and heart failure monographs (2026); Signs and Symptoms of Stroke (2026); Osteoporosis to Prevent Fractures: Screening (2025); Adult Immunization Schedule by Age (2026)
Follow-up: Zoster dose 1 and Tdap given today; second zoster dose in two to six months. Review in three months with a metabolic panel. Cardiology review at six months from consultation. Call 911 for any BE FAST sign. [S]